Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BeOne Medicines's Debt-to-EBITDA or its related term are showing as below:
ONC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.18 Med: -0.35 Max: 1.77
Current: 1.27
During the past 13 years, the highest Debt-to-EBITDA Ratio of BeOne Medicines was 1.77. The lowest was -3.18. And the median was -0.35.
ONC's Debt-to-EBITDA is ranked worse than 51.2% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs ONC: 1.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BeOne Medicines Debt-to-EBITDA Related Terms
BeOne Medicines Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs ALNY, RVMD, RPRX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BeOne Medicines's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
BeOne Medicines (ONC) has a Debt-to-EBITDA of 0.86 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BeOne Medicines. According to the industry distribution chart, BeOne Medicines ranks #149 out of 291 companies in the Biotechnology industry, placing it in the top 51.2%.
Is BeOne Medicines' Debt-to-EBITDA too high?
BeOne Medicines' current Debt-to-EBITDA is 0.86. The Biotechnology industry median Debt-to-EBITDA is 1.14. BeOne Medicines' value of 0.86 is 24.6% below this industry median. Based on the distribution chart, BeOne Medicines ranks #149 out of 291 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Debt-to-EBITDA compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #149 out of 291 companies for Debt-to-EBITDA. This places BeOne Medicines in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. BeOne Medicines' value of 0.86 is 24.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Debt-to-EBITDA of 0.86 is 24.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BeOne Medicines. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Debt-to-EBITDA is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $371.18, compared to a current price of $325.90 — trading 12.2% below its estimated fair value. The current Debt-to-EBITDA is 0.86 and 24.6% below the Biotechnology industry median of 1.14. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Debt-to-EBITDA is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $325.90 is trading 12.2% below its estimated GF Value™ of $371.18.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Debt-to-EBITDA: 0.86
GF Value™: $371.18 vs. price of $325.90 (12.2% below fair value)
Industry Position: 24.6% below the Biotechnology median (#149 of 291)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for ONC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
